Indiana University

The ASPIRE algorithm uses cell phenotype information from bone marrow samples to predict which patients will relapse and which will go into remission. 

Roche, Eli Lilly, and others aim to elucidate differences in T2D patients in order to develop better diagnostic tools and new treatments.